Lower CD226 and high TIGIT may predict poor prognosis in AML patients and the imbalance in TIGIT/CD226 axis may be the immune checkpoint barrier responsible for T-cell immune dysfunction [56]. This evidence concerns the gene CD226 and acute myeloid leukemia.